Curium Announces First Patients in Europe Injected With PYLCLARI® – an Innovative 18F-PSMA Pet Tracer Indicated in Patients With Prostate Cancer
PARIS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that in partnership with its exclusive distributor SYN Innovation Laboratories in Greece, the first patients in Greece have been injected with PYLCLARI® (INN: Piflufolastat (18F) also known as (18 F)-DCFPyL, indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in patients with prostate cancer in the following clinical se
Source: yahoo.com
